Figure 7 | Scientific Reports

Figure 7

From: A 3-month-delayed treatment with anatabine improves chronic outcomes in two different models of repetitive mild traumatic brain injury in hTau mice

Figure 7

Immunofluorescent analysis of GFAP and NFkB. (A) Representative images of NFkB/GFAP in cortex, corpus callosum (CC) and hippocampus. (B,C) Quantification of area coverage of NFkB in cortex and GFAP in CC, respectively, in 5r-mTBI cohort. (D,E) quantification of area coverage of NFkB in cortex and GFAP in CC, respectively, in 24r-mTBI cohort. In the 24r-mTBI group, TBI produced a significant increase of GFAP in CC ((E), p < 0.001) and of NFkB in cortex ((D), p < 0.0001) compared to 24r-sham-vehicle. Similarly, in the 5r-mTBI group, TBI induced GFAP ((C), p < 0.001) and NFkB ((B), p < 0.0001) immunoreactivity compared to 5r-sham-vehicle mice. Treatment with anatabine decreased GFAP (24r-mTBI p < 0.01; 5r-mTBI p < 0.01) and NFkB (24r-mTBI p < 0.001; 5r-mTBI p < 0.0001) in r-mTBI mice compared to the respective r-mTBI-vehicle mice. Data analyzed using two-way ANOVA. Scale bar equal 200 µm.

Back to article page